Small Cap
Diagnostics & Research
Stocks Ranked by
Market Capitalization
| Name | Market cap | Price |
Price change % |
|
|---|---|---|---|---|
1
GeneDx Holdings
WGS
$1.9B
| $1.9B | $63.61 | 9.41% |
|
2
Personalis
PSNL
$1.67B
| $1.67B | $15.65 | 1.76% |
|
|
FRNM
3
Freenome Inc
FRNM
$1.26B
| $1.26B | $11.75 | 4.39% |
|
4
Opko Health
OPK
$1.14B
| $1.14B | $1.53 | 4.97% |
|
5
Castle Biosciences
CSTL
$976M
| $976M | $31.96 | 5.44% |
|
6
Fulgent Genetics
FLGT
$545M
| $545M | $19.81 | 7.17% |
|
7
Myriad Genetics
MYGN
$381M
| $381M | $3.98 | 8.51% |
|
Small Cap Diagnostics & Research Stocks at a Glance
Diagnostics and research companies run laboratory testing, imaging, and analytical services, and supply the instruments behind them. Testing volumes are recurring and largely non-discretionary, while research-tools demand follows pharma and academic R&D budgets.
There are 7 small cap Diagnostics & Research stocks — companies in the Diagnostics & Research industry with a market cap between $250M and $2B — worth a combined $7.87B.
The largest by market cap are GeneDx Holdings (WGS) at $1.9B, Personalis (PSNL) at $1.67B and Freenome Inc (FRNM) at $1.26B.
Among institutional investors, Personalis (PSNL) drew the most net new fund positions in Q2 2026: 42 funds opened new positions, taking total fund holders up 18 (13%) quarter-over-quarter.
- Combined market cap: $7.87B across 7 stocks.
- Small Cap: market cap between $250M and $2B.
- Largest constituent: GeneDx Holdings (WGS), $1.9B market cap.
- Most net new fund positions in Q2 2026: Personalis (PSNL), +18 holders.
Market caps and prices updated daily; fund activity based on aggregated SEC 13F filings for Q2 2026.